Abstract:Importance Colorectal cancer (CRC) is the third most common cause of cancer mortality worldwide with more than 1.85 million cases and 850 000 deaths annually. Of new colorectal cancer diagnoses, 20% of patients have metastatic disease at presentation and another 25% who present with localized disease will later develop metastases. Observations Colorectal cancer is the third most common cause of cancer mortality for men and women in the United States, with 53 200 deaths projected in 2020. Among people diagnosed with metastatic colorectal cancer, approximately 70% to 75% of patients survive beyond 1 year, 30% to 35% beyond 3 years, and fewer than 20% beyond 5 years from diagnosis. The primary treatment for unresectable metastatic CRC is systemic therapy (cytotoxic chemotherapy, biologic therapy such as antibodies to cellular growth factors, immunotherapy, and their combinations.) Clinical trials completed in the past 5 years have demonstrated that tailoring treatment to the molecular and pathologic features of the tumor improves overall survival. Genomic profiling to detect somatic variants is important because it identifies the treatments that may be effective. For the 50% of patients with metastatic CRC with KRAS/NRAS/BRAF wild-type tumors, cetuximab and panitumumab (monoclonal antibodies to the epithelial growth factor receptor [EGFR]), in combination with chemotherapy, can extend median survival by 2 to 4 months compared with chemotherapy alone. However, for the 35% to 40% of patients with KRAS or NRAS sequence variations (formerly termed mutations), effective targeted therapies are not yet available. For the 5% to 10% with BRAF V600E sequence variations, targeted combination therapy with BRAF and EGFR inhibitors extended overall survival to 9.3 months, compared to 5.9 months for those receiving standard chemotherapy. For the 5% with microsatellite instability (the presence of numerous insertions or deletions at repetitive DNA units) or mismatch repair deficiency, immunotherapy may be used in the first or subsequent line and has improved treatment outcomes with a median overall survival of 31.4 months in previously treated patients. Conclusions and Relevance Advances in molecular profiling of metastatic CRC facilitate the ability to direct treatments to the biologic features of the tumor for specific patient subsets. Although cures remain uncommon, more patients can anticipate extended survival. Genomic profiling allows treatment selection so that more patients derive benefit and fewer are exposed to toxicity from ineffective therapies.

Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer

Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance

Recent Advances in Biomarkers for the Targeted Therapy of Metastatic Colorectal Cancer

Comprehensive review of targeted therapy for colorectal cancer

Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer

Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment

EGFR-Based Targeted Therapy for Colorectal Cancer-Promises and Challenges

Molecular Network of Colorectal Cancer and Current Therapeutic Options

Molecularly targeted drugs for metastatic colorectal cancer.

Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review.

Advances in Epigenetic Biomarker Research in Colorectal Cancer.

Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives.

Targeted therapy of colorectal cancer and its drug resistance mechanism

New developments in targeted therapy for metastatic colorectal cancer

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance

Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer

Translational research of new developments in targeted therapy of colorectal cancer

Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy

Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer

Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling